CURE:XETRA:XETRA-VanEck Genomics and Healthcare Innovators UCITS ETF EUR (EUR)

ETF | Others |

Last Closing

USD 19.776

Change

+0.09 (+0.47)%

Market Cap

N/A

Volume

600.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-06 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.52 (+0.97%)

USD 445.28B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.22 (+1.27%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.42 (+1.50%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.33 (+1.14%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.39 (+1.52%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

+0.62 (+1.33%)

USD 102.61B
8R80:XETRA Amundi Index Solutions - Amund..

+1.02 (+0.72%)

USD 98.84B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.22 (+0.42%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+1.19 (+1.11%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+6.92 (+1.13%)

USD 80.38B

ETFs Containing CURE:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.09% 86% B+ 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.09% 86% B+ 81% B-
Trailing 12 Months  
Capital Gain 9.57% 41% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.57% 40% F 43% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.46% 18% F 21% F
Dividend Return -1.46% 18% F 20% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 6.73% 79% B- 84% B
Risk Adjusted Return -21.62% 17% F 18% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.